‘Unlikely to transform patient care’: GSK punts top late-stage drug after PhIII data disappoint
GSK has reached the end of the road with otilimab, once hailed as a top prospect for rheumatoid arthritis, after a trio of Phase III trials yielded disappointing results.
Former R&D chief Hal Barron forged ahead with the late-stage endeavors for otilimab despite it flunking a Phase II trial. While two of the three trials met their primary endpoints, GSK says looking at the data so far, “the efficacy demonstrated is unlikely to transform patient care for this difficult-to-treat patient population.” As a result, it is scrapping plans for regulatory submissions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.